A-type voltage-gated potassium channel KCND3 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14A-type voltage-gated potassium channel KCND3 shows approved-linked disease relevance led by atrial fibrillation. 1 more disease program remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q9UK17. Start with atrial fibrillation, then reuse UniProt Q9UK17 as the stable protein anchor across project notes and exports.
Start with atrial fibrillation, then reuse UniProt Q9UK17 as the stable protein anchor across project notes and exports.
A-type voltage-gated potassium channel KCND3 shows approved-linked disease relevance led by atrial fibrillation. 1 more disease program remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with atrial fibrillation because it currently carries approved-linked support. Linked drugs include VERNAKALANT HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyA-type voltage-gated potassium channel KCND3
Review this target as A-type voltage-gated potassium channel KCND3, mapped to UniProt Q9UK17. Sequence length is 655 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats A-type voltage-gated potassium channel KCND3 as ChEMBL target CHEMBL1964, mapped to UniProt Q9UK17. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether A-type voltage-gated potassium channel KCND3 is the right protein anchor across sources, using UniProt Q9UK17 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why atrial fibrillation is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | A-type voltage-gated potassium channel KCND3 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q9UK17 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | A-type voltage-gated potassium channel KCND3 |
| UniProt Accession | Q9UK17 |
| Component Type | Protein |
| Sequence Length | 655 aa |
A-type voltage-gated potassium channel KCND3
Review this target as A-type voltage-gated potassium channel KCND3, mapped to UniProt Q9UK17. Sequence length is 655 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
A-type voltage-gated potassium channel KCND3 shows approved-linked disease relevance led by atrial fibrillation. 1 more disease program remain visible in the same review block.
Start review with atrial fibrillation because it currently carries approved-linked support. Linked drugs include VERNAKALANT HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL44297 | 5.85 | IC50 | 1400.0 | Preclinical |
| CHEMBL4065169 | 5.64 | IC50 | 2300.0 | Preclinical |
| CHEMBL569185 | 5.41 | IC50 | 3870.0 | Preclinical |
| CHEMBL2042163 | 5.24 | IC50 | 5800.0 | Preclinical |
| CHEMBL4104525 | 5.08 | IC50 | 8300.0 | Preclinical |
| CHEMBL243664 | 5.03 | IC50 | 9300.0 | Preclinical |
| CHEMBL4475999 | 4.96 | IC50 | 11000.0 | Preclinical |
| CHEMBL1346 | 4.9 | IC50 | 12589.25 | Approved |
| CHEMBL1382 | 4.9 | IC50 | 12589.25 | Approved |
| CHEMBL5191783 | 4.55 | IC50 | 28000.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 43 | 23 | 4.3 |
| assay format | 1 | 1 | 5.8 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 14 | 2 | 5.2 |
| single protein format | 13 | 4 | 5.2 |
| assay format | 2 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 8 | 0 | — |
| single protein format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 3 | 1 | 4.5 |